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Melanin is produced in melanocytes and stored in 
melanosomes. In spite of its beneficial sun- protective effect, 
abnormal accumulation of melanin results in esthetic 
problems. Hydroquinone, competing with tyrosine, is a 
major ingredient in topical pharmacological agents. How-
ever, frequent adverse reactions are amongst its major 
limitation. To solve this problem, several alternatives such as 
arbutin, kojic acid, aloesin, and 4-n-butyl resorcinol have 
been developed. Herein, we classify hypopigmenting agents 
according to their mechanism of action; a) regulation of 
enzyme, which is subdivided into three categories, i) 
regulation of transcription and maturation of tyrosinase, ii) 
inhibition of tyrosinase activity, and iii) post-transcriptional 
control of tyrosinase; b) inhibition of melanosome transfer, 
and c) additional mechanisms such as regulation of the 
melanocyte environment and antioxidant agents. (Ann 
Dermatol 24(1) 1∼6, 2012)
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INTRODUCTION
Melanin plays an important role in protecting the skin 
from ultraviolet light. It also determines skin color and 
influences phenotypic appearances. However, abnormal 
accumulation of melanin may lead to esthetic problems. 
Hydroquinone (HQ) is a major ingredient in topical phar-
macological agents that are used for hyperpigmentary 
disorders. However, HQ is frequently associated with a 
high rate of adverse effects
1,2.
Therefore, several topical hypopigmenting agents have 
been developed and widely used (Table 1). This review 
summarizes the different approaches that have been 
implemented to achieve hypopigmentation and classify 
them on the basis of their mechanisms. 
TOPICAL HYPOPIGMENTING AGENTS HQ 
IN MELASMA 
Treatment of melasma is difficult and a number of agents 
have been used for this intractable condition. To date, the 
most effective treatment is a triple-combination cream that 
contains 4% HQ, 0.05% tretinoin and 0.01% fluocinolone 
acetonide
3. HQ is the most commonly used tyrosinase 
inhibitor. Oxidation products of HQ result in oxidative 
damage of membrane lipids and proteins, including tyro-
sinase, and depletion of glutathione
4. However, HQ is not 
commonly used in cosmetics because of long-term compli-
cations
5. Tretinoin is used as an anti-wrinkle agent. How-
ever, it is also reported that topical retinoid is effective in 
the treatment of pigmentary disorders or can be combined 
with other topical agents
6. The third ingredient featured in 
triple combination products is corticosteroids. Steroids are 
effective in the suppression of cytokines such as endothelin- 
1 and granulocyte macrophage colony-stimulating factor 
(GM-CSF), which mediate ultraviolet (UV)-induced res-H Kim, et al
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Fig. 1. Schematic illustration of 
possible strategies for inhibition of 
melanogenesis. UV: ultraviolet.
Table 1. Classification of hypopigmenting agents. Compounds are divided on the basis of their reported mechanism of interference
with melanogenesis
5
  Before melanin synthesis
    Regulation of tyrosinase transcription
      T G F - β1, TNF-α, IL-1α,  β, IL-6, lysophosphatidic acid, C2-ceramides, sphingosine-1-phosphate
      Sphingosylphosphorylcholine, tretinoin
    Inhibition of tyrosinase maturation
      Glucosamine, tunicamycin, glycosphingolipid, calcium d-pantetheine- S-sulphonate
  During melanin synthesis
    Inhibition of tyrosinase activity
      Hydroquinone, arbutin, kojic acid, 4-n-butylresorcinol, phenolic compounds, 4-hydroxy-anisole, methyl gentisate, 
       4-S-CAP & derivatives, ellagic acid, oxyresveratrol, resveratrol, aloesin, azelaic acid  
  After melanin synthesis
    Posttranscriptional control of tyrosinase
      Linoleic acid, α-linolenic acid, phospholipase D2
    Inhibition of melanosome transfer
      Niacinamide (Vitamin B3), serine protease inhibitors, lecthins and neoglycoproteins, RW-50353, soybean.milk extracts
  Regulation of melanocytes environment
      Corticosteroids, glabridin
  Antioxidant agents
      α-Tocopherol, ascorbic acid, ascorbic acid palmitate, D, L-α TF, VC-PMG, methimazole, 
       hydrocoumarins (6-hydroxy-3,4-dihydrocoumarins), thioctic acid (α-lipoic acid), phenol/catechol
TGF: transforming growth factor, TNF: tumor necrosis factor, IL: interleukin, TF: α-tocopherol ferulate, VC-PMG: magnecium- 
Ascorbyl-2-phosphate.
ponses
7,8. By using a triple-combination cream, combined 
effects can be expected for the treatment of pigmentary 
conditions. 
The efficacy and safety of triple-combination creams have 
been reported in several studies
9. In one study, 26.1% 
showed a complete clearing of melasma by week 8
10. In 
another multicenter study, global evaluations revealed that 
75% of patients showed “moderate or marked improve-
ment” or were “almost clear” or “clear” by week 8. These 
results showed that a triple-combination cream is a rapidly 
effective topical agent for the treatment of melasma
11. 
However, in one study, 57% of patients experienced at 
least one treatment-related adverse reaction, although it 
was claimed to be mild and transient in nature
12. In parti-
cular, post-inflammatory hyperpigmentation should be 
expected in darker-skinned patients
13. A multicenter study 
was also performed to compare the efficacy and safety of a 
triple-combination cream in Asian patients. The results Topical Hypopigmenting Agents for Pigmentary Disorders and Their Mechanisms of Action
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showed that a triple-combination cream was also effective 
in Asian patients with tolerable adverse reactions. Although 
most adverse events were mild, almost 50% of patients 
reported the incidence of related adverse events
14. Thus, it 
should be noted that triple-combination creams are 
effective for melasma, but can have a high frequency of 
adverse reactions. 
CLASSIFICATION OF TOPICAL AGENTS FOR 
PIGMENTARY CONDITIONS
At present, the most effective hypopigmenting agents are 
tyrosinase inhibitors. However, melanogenesis can be 
controlled by regulating (i) the transcription and activity of 
enzymes such as tyrosinase, tyrosinase-related protein-1 
(TRP-1), tyrosinase-related protein-2, and/or peroxidase; 
(ii) the uptake and distribution of melanosome in keratino-
cytes and (iii) melanin and melanosome degradation and 
turnover of “pigmented” keratinocytes
5. However, it is 
very clear that hypopigmenting agents can work by diffe-
rent combined mechanisms. Furthermore, melanogenesis 
is controlled by additional factors via keratinocytes, fibro-
blasts and also by local and/or systemic conditions (Fig. 1). 
Regulation of enzymes 
1) Regulation of transcription and maturation of tyrosi-
nase 
Transcription of genes encoding tyrosinase and TRP-1 is 
under the control of the microphthalmia transcription 
factor (MITF)
15. Mitf is a critical transcription factor for 
both melanocyte proliferation and melanogenesis. As Mitf 
is regulated by the Wnt signaling pathway as well as 
cAMP, and by both p38 signaling and the MAP kinase 
pathway, any agents that can potentially regulate these 
signaling pathways will also affect Mitf and melanogene-
sis. Although it is not clinically available, sustained extra-
cellular signal regulated kinase (ERK) activation by sphin-
gosine-1-phosphate (S1P) can lead to MITF phosphory-
lation and degradation, which in turn are responsible for 
decreased melanin synthesis
16. Transforming growth factor 
(TGF-β1) also plays an inhibitory role in melanogenesis. 
TGF-β1 induced a significant delay in ERK activation and 
ERK-induced down-regulation of Mitf
17. Furthermore, 
lysophosphatidic acid and C2 ceramides are able to 
induce Mitf degradation or decrease Mitf expression
18-20. 
These are examples that inhibit melanogenesis by trans-
criptional regulation of the tyrosinase gene. Tyrosinase is a 
glycosylated protein. Therefore, glucosamine or tunicamy-
cin, which are specific inhibitors of lipid carrier-depen-
dent glycosylation, can induce hypopigmentation
21. In 
addition, calcium D-pantetheine-S-sulphonate (PaSSO3Ca) 
causes an inhibition of melanogenic enzymes possibly 
through the alteration of tyrosinase and TRP-1 glycosy-
lation without affecting their expression
22.
2) Inhibition of tyrosinase activity 
There are several tyrosinase inhibitors that have been used 
to produce hypopigmenting topical agents or cosmetics. 
Arbutin, a naturally occurring HQ beta-D-gluconopyrano-
side is commonly used
23. Arbutin decreases tyrosinase 
activity without affecting mRNA expression and inhibits 
5,6-dihydroxyindole-2-carboxylic acid (DHICA) polyme-
rase activity
24. Kojic acid (5-hydroxy-2-hydroxymethyl-4H- 
pyran-4-one) was also a commonly used antibiotic agent 
produced by species of Asperigillus and Penicillum
25.
Among these, 4-n-butylresorcinol has been characterized 
as a strong tyrosinase inhibitor
26. We compared the 
hypopigmenting effects of HQ and 4-n-butyl resorcinol 
and showed that HQ (100μM) and 4-n-butyl resorcinol 
(10μM) had similar tyrosinase inhibition activities. These 
finding suggests that 4-n-butyl resorcinol is a more potent 
tyrosinase inhibitor than HQ. Thus, the hypopigmenting 
effect can increase if the concentration of 4-n-butyl resor-
cinol is increased. However, a cautious increase will be 
necessary to ensure both efficacy and safety. Positive 
hypopigmenting effects of 4-n-butyl resorcinol have pre-
viously been demonstrated
27. 
Generally, phenolic compounds are known as hypopig-
menting agents because of their ability to serve as alter-
native substrates for tyrosinase
28. 
3) Post-transcriptional control of tyrosinase 
There are examples of agents that inhibit melanogenesis 
by the increased degradation of tyrosinase proteins. Unsa-
turated linoleic acid decreases tyrosinase activity, whereas 
saturated palmitic or stearic acids increases tyrosinase 
activity. Also, topical application of linolenic, linoleic and 
oleic acids produce a hypopigmenting effect on guinea 
pig skin stimulated with UV light
29. It is reported that 
linoleic acid decreases the amount of tyrosinase through 
increased tyrosinase ubiquitination and degradation by the 
proteasome
30,31. In addition, other agents like phospholipase 
D2 decrease melanogenesis through the same ubiquitin- 
mediated degradation of tyrosinase
32.
Inhibition of melanosome transfer
Melanosomes are specialized organelles in which melanin 
is synthesized and deposited. The addition of TGF-β1 to 
cultured melanocytes produced less pigmented melano-
somes even when the cells were concomitantly treated 
with  αMSH to increase their fully melanized melano-H Kim, et al
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somes
33. It is also reported that ERK activation by S1P can 
lead to hypopigmentation
16. Interestingly, decreased mela-
nization of melanosomes was also found in S1P treated 
melanocytes (unpublished data). Moreover, S1P-treated 
cells showed undifferentiated early stage melanosomes, 
whereas control cells showed internal fibrils and dense 
pigments in melanosomes. These findings suggest that inhi-
bition of melanosome formation can be a good strategy to 
control melanogenesis. However, there are no agents that 
are currently available to meet this requirement. 
Melanosome formation is an important step in melanog-
nesis and melanosomes need to be transferred to keratino-
cytes from melanocytes for the completion of this step. 
Thus, the inhibition of melanosome transfer can produce a 
hypopigmenting effect. Theoretically, the inhibition of 
serine protease can result in an impaired activation of 
protease-activated receptor 2  on the keratinocyte leading 
to the accumulation of melanosomes within the melano-
cyte
34. Clinically, niacinamide (Vitamin B3), which is 
commonly used to manufacture cosmetics, has been 
found to inhibit melanosome transfer to keratinocytes both 
in vitro and in vivo
35. 
Additional mechanisms
1) Regulation of melanocytes environment
Endothelin 1 (ET-1), which is produced by keratinocytes 
after exposure to inflammatory stimuli or UV exposure, 
stimulates melanogenesis. ET-1 has strong stimulatory 
effects both on DNA synthesis and melanization in human 
melanocytes. Thus, topical application of M. chamomilla 
extract inhibits ultraviolet B (UVB)-induced pigmentation 
by inhibiting ET-1 effects
36. 
Clinically, it is well-known that topical corticosteroids 
have strong anti-inflammatory effects. They have been 
used for the treatment of melasma to decrease irritation 
caused by hypo-pigmenting agents
37, and work by the 
suppression of cytokines through the inhibition of nuclear 
factor kappa B (NF-κB) activation. Topical steroids can be 
effective by the suppression of cytokines such as 
endothelin-1 and GM-CSF, which mediate UV-induced 
pigmentation
7,8.
There are several ingredients with anti-inflammatory 
activity. Glabridin, the main component of hydrophobic 
fraction of licorice extracts decreases tyrosinase activity in 
B16 melanoma cells and inhibits UVB-induced skin pig-
mentation as well as erythema. The capability to inhibit 
cyclooxygenase activity and superoxide anion production 
implies that this anti-inflammatory effect requires an inter-
ference with the arachidonic acid cascade. Consequently, 
protection against oxidative stress plays a key role in 
controlling melanogenesis
38. 
2) Antioxidant agents
In general, antioxidants exhibit hypopigmenting effects by 
interacting with o-quinones, thus avoiding the oxidative 
polymerization of melanin intermediates, or with copper 
at the active site of tyrosinase. In addition, antioxidant 
agents can regulate the signaling process by scavenging 
ROS in the skin
39. For example, ascorbic acid can interfere 
with melanization by interaction with copper ions at 
tyrosinase and reduction of dopaquinone and DHICA 
oxidation
40,41. α-Tocopherol and its derivatives can also 
regulate melanogenesis. The antioxidant property affects 
the lipid peroxidation of membranes and increases the 
intracellular glutathione content
42. 6-Hydroxy-3,4-dihydro-
cumarins, another novel type of antioxidant, have an anti- 
melanogenic activity in cultured normal human melano-
cytes at non-cytotoxic concentrations without interfering 
with tyrosinase activity
43. The acceleration of glutathione 
synthesis and the inhibition of tyrosinase transfer may be 
the mechanism of action
44.  α-lipoic acid, a disulfide 
derivative of octanoic acid, has been reported to prevent 
UV-induced oxidative damage, mainly through the down- 
modulation of NF-κB activation. In addition, this agent is 
known to inhibit tyrosinase activity by possibly chelating 
the copper ions
45. Peroxidase is involved in the polymeri-
zation of melanogenic intermediates
46. Based on this, the 
inhibition of peroxidase can decrease melanogenesis by 
reducing the polymerization of eumelanin
47. Methima-
zole, an antithyroid agent belonging to the thionamide 
group, shows inhibitory action towards tyrosinase and 
peroxidase
48. Mild to moderate inhibition of melanization 
can be expected with morphological changes of melano-
cytes in animal models. 
3) Combination of multifunction hypopigmenting agents
Recently, we reported that terrein, a bioactive fungal 
metabolite isolated from a Penicillium  species, reduces 
melanin synthesis by reducing tyrosinase production via 
ERK activation, and that this is followed by MITF downre-
gulation
49. Interestingly, we also found that terrein decrea-
ses melanogenesis through ubiquitin-dependent proteaso-
mal degradation as well as decreased expression of its 
mRNA
50. Thus, terrein can be an example of a hypopig-
menting agent that inhibits melanogenesis by dual action 
including the down-regulation of transcription and up- 
regulation of degradation. 
In contrast to terrein with multifunction, the combined use 
of two agents with different action mechanisms can be 
additive in terms of total effects. As already described, 
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or MITF degradation, and also had no effect on cAMP 
response element binding protein  phosphorylation, which 
stimulates MITF expression
26. However, 4-n-butylresor-
cinol showed an additive effect in combination with hino-
kitiol, which reduces MITF expression. Thus, the combina-
tion of these two agents with different action mechanisms 
can be another strategy to increase the efficacy of these 
agents. 
CONCLUSION
Recently, melanocyte biology has made remarkable pro-
gress. However, the pathogenic mechanisms underlying 
acquired hyperpigmentation have not been completely 
understood. Even though these mechanisms need to be 
explored further, our present understanding has improved 
greatly, which has contributed to the enhancement of 
diagnosis and treatment of pigmentary conditions. In 
particular, the finding that the dermal microenvironment 
can affect epidermal pigmentation through dermal dege-
neration or vascular dilatation has had a significant in-
fluence. These findings suggest that environmental effects 
on melanogenesis are very important. In addition, the 
combined use of multiple agents with different actions can 
show additive effects. As already described, 4-n-butylre-
sorcinol is a strong tyrosinase inhibitor, whereas a signal 
regulator such as terrain affects pigmentation through 
ERK-induced MITF degradation. Thus, the combination of 
multiple agents with different mechanisms of action can 
be another strategy to increase the efficacy of these agents. 
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